Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment

Journal of Alzheimer's Disease

Volumn 47, Issue 3, 2015, Pages 691-704

  Nordberg, Agneta ^a,b   Kadir, Ahmadul ^a,b   Andreasen, Niels ^b   Almkvist, Ove ^a,c   Wall, Anders ^d   Blennow, Kaj ^e   Langstrom, Bengt ^d   Zetterberg, Henrik ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; cerebral glucose metabolism; cerebrospinal fluid; phenserine; positron emission tomography

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; DONEPEZIL; GLUCOSE; PHENSERINE; PLACEBO; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; NOOTROPIC AGENT; PEPTIDE FRAGMENT; PHYSOSTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; MALE; METABOLIC RATE; NEUROIMAGING; OPEN STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BRAIN; CEREBROSPINAL FLUID; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SCINTISCANNING; TIME FACTOR; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOMARKERS; BRAIN; COGNITION; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; HUMANS; MALE; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PHYSOSTIGMINE; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938700926     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132474     Document Type: Article

References (92)

1. Salloway S, Mintzer J, Weiner MF, Cummings JL (2008) Disease-modifying therapies in Alzheimers disease. Alzheimers Dement 4, 65-79.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
3. Selkoe DJ (2011) Alzheimers disease. Cold Spring Harb Perspect Biol 3, pii: a004457.
4. Wolfe MS (2006) Shutting down Alzheimers. Sci Am 294, 72-79.
5. Klein WL (2002) Abeta toxicity in Alzheimers disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41, 345-352.
6. Selkoe DJ (2001) Alzheimers disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
7. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11, 213-228.
8. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid betaprotein: Synaptic and network dysfunction. Cold Spring Harb Perspect Biol 2, a006338.
9. Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6, 108-119.
10. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimers disease: Clinical trials and drug development. Lancet Neurol 9, 702-716.
11. Delrieu J, Ousset PJ, Caillaud C, Vellas B (2012) Clinical trials in Alzheimers disease: Immunotherapy approaches. J Neurochem 120 (Suppl 1) , 186-193.
12. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators (2014) Two phase 3 trials of babineuzumab in mild-to-moderate Alzheimers diease. N Engl J Med 370, 322-333.
13. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F (2012) New pharmacological strategies for treatment of Alzheimers disease: Focus on disease modifying drugs. Br J Clin Pharmacol 73, 504-517.
14. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH (2001) Phenserine regulates translation of beta-Amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 98, 7605-7610.
15. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, Giordano T, Sambamurti K, Greig NH (2007) The experimental Alzheimers disease drug posiphen [ (+) -phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320, 386-396.
16. Lilja AM, Rojdner J, Mustafiz T, Thome CM, Storelli E, Gonzalez D, Unger-Lithner C, Greig NH, Nordberg A, Marutle A (2013) Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-beta levels. PLoS One 8, e58752.
17. Marutle A, Ohmitsu M, Nilbratt M, Greig NH, Nordberg A, Sugaya K (2007) Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc Natl Acad Sci U S A 104, 12506-12511.
18. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B (2011) Biomarkers for Alzheimers disease therapeutic trials. Prog Neurobiol 95, 579-593.
19. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6, 78-87.
20. Mosconi L, McHugh PF (2011) FDG-And amyloid-PET in Alzheimers disease: Is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging 55, 250-264.
21. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimers disease. Brain 129, 2856-2866.
22. Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Langstrom B, Nordberg A (2012) Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimers disease. Neurobiol Aging 33, 198.e1-198.e14
23. Kadir A, Nordberg A (2010) Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med 51, 1418-1430.
24. Nordberg A (2009) The future: New methods of imaging exploration in Alzheimers disease. Front Neurol Neurosci 24, 47-53.
25. Jack CR Jr., Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease. Brain 132, 1355-1365.
26. Scheinin NM, Aalto S, Koikkalainen J, Lotjonen J, Karrasch M, Kemppainen N, Viitanen M, Nagren K, Helin S, Scheinin M, Rinne JO (2009) Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 73, 1186-1192.
27. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
28. Blennow K (2005) CSF biomarkers for Alzheimers disease: Use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 5, 661-672.
29. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimers disease. Lancet Neurol 2, 605-613.
30. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimers disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.
31. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N (2007) Longitudinal stability of CSF biomarkers in Alzheimers disease. Neurosci Lett 419, 18-22.
32. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A (2007) Intra-individual stability of CSF biomarkers for Alzheimers disease over two years. J Alzheimers Dis 12, 255-260.
33. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Larksater M, Winblad B, Zetterberg H, Blennow K, Langstrom B, Nordberg A (2008) Effect of phenserine treatment on brain functional activity and amyloid in Alzheimers disease. Ann Neurol 63, 621-631.
34. Winblad B, Giacobini E, Frolich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH (2010) Phenserine efficacy in Alzheimers disease. J Alzheimers Dis 22, 1201-1208.
35. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34, 939-944.
36. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319.
37. Scholl M, Almkvist O, Axelman K, Stefanova E, Wall A, Westman E, Langstrom B, Lannfelt L, Graff C, Nordberg A (2011) Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging 32, 1388-1399.
38. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multipletime uptake data. J Cereb Blood Flow Metab 3, 1-7.
39. Minoshima S, Frey KA, Foster NL, Kuhl DE (1995) Preserved pontine glucose metabolism in Alzheimer disease: A reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 19, 541-547.
40. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K (2005) Simultaneous measurement of betaamyloid ( 1-42) , total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51, 336-345.
41. Bergman I, Blomberg M, Almkvist O (2007) The importance of impaired physical health and age in normal cognitive aging. Scand J Psychol 48, 115-125.
42. Jacobsen JS, Reinhart P, Pangalos MN (2005) Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimers disease. NeuroRx 2, 612-626.
43. Cummings JL, Morstorf T, Zhong K (2014) Alzheimers disease drug development pipeline: Few candidates, frequent failures. Alzheimers Res Ther 6, 37.
44. Jack CR Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade. Lancet Neurol 9, 119-128.
45. Nordberg A (2007) Amyloid imaging in Alzheimers disease. Curr Opin Neurol 20, 398-402.
46. Nordberg A (2011) Molecular imaging in Alzheimers disease: New perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 3, 34.
47. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A (2010) High PIB retention in Alzheimers disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 7, 56-66.
48. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 1456-1465.
49. Jack CR, Jr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC (2012) Anoperational approach to National Institute on Aging-Alzheimers Association criteria for preclinical Alzheimer disease. Ann Neurol 71, 765-775.
50. Klein J (2007) Phenserine. Expert Opin Investig Drugs 16, 1087-1097.
51. Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Moller HJ, Hampel H, Davidsson P, Blennow K (2003) Measurement of alpha-And beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 183, 74-80.
52. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65, 1102-1107.
53. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimers disease: A multicenter study. Mol Psychiatry 15, 138-145.
54. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, Wallin A, Blennow K, Zetterberg H (2012) Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 30, 767-778.
55. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H (2012) Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimers disease. Neuromolecular Med 14, 65-73.
56. Bailey JA, Lahiri DK (2010) A novel effect of rivastigmine on pre-synaptic protein neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimers disease. J Neurochem 112, 843-853.
57. Bailey JA, Ray B, Greig NH, Lahiri DK (2011) Rivastigmine lowers Aβ and increases sAPPa levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PloS One 6, e21954.
58. Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH (2012) Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: Target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry 83, 894-902.
59. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191-199.
60. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058.
61. Zou K, Gong JS, Yanagisawa K, Michikawa M (2002) A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 22, 4833-4841.
62. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M (2003) Amyloid beta-protein (Abeta) 1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem 87, 609-619.
63. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E (2007) Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27, 627-633.
64. Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, Van Broeckhoven C (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 27, 686-695.
65. Grant JL, Ghosn EE, Axtell RC, Herges K, Kuipers HF, Woodling NS, Andreasson K, Herzenberg LA, Steinman L (2012) Reversal of paralysis and reduced inflammation from peripheral administration of beta-Amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med 4, 145ra105.
66. Vukovich R, Perneczky R, Drzezga A, Forstl H, Kurz A, Riemenschneider M (2009) Brain metabolic correlates of cerebrospinal fluid beta-Amyloid 42 and tau in Alzheimers disease. Dement Geriatr Cogn Disord 27, 474-480.
67. Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Itoh M, Iwatsubo T, Tomita T, Sasaki H (1999) Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans. Neurosci Lett 273, 203-207.
68. Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S (2009) Preclinical evidence of Alzheimer changes: Convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol 66, 632-637.
69. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K (2006) Determination of beta-Amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 5, 1010-1016.
70. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K (2007) Prediction of Alzheimers disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23, 316-320.
71. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105.
72. Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res The 2, 7.
73. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimers disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
74. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33, 67-73.
75. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69, 1002-1010.
76. Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M (2013) Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 5, 194re192.
77. Hellstrom-Lindahl E, Moore H, Nordberg A (2000) Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 74, 777-784.
78. Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A (2003) Cerebral glucose metabolism, cerebrospinal fluid-beta-Amyloid1-42 (CSF-Abeta42) , tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 338, 159-163.
79. Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, Shoji M (1999) Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimers disease. Neurosci Lett 267, 65-68.
80. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimers disease treatment studies. Am J Psychiatry 159, 738-745.
81. Stefanova E, Wall A, Almkvist O, Nilsson A, Forsberg A, Langstrom B, Nordberg A (2006) Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimers disease. J Neural Transm 113, 205-218.
82. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM (2003) Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: Results of a 24-week, doubleblind, placebo-controlled study. Am J Geriatr Psychiatry 11, 169-177.
83. Chen K, Langbaum JB, Fleisher AS, Ayutyanont N, Reschke C, Lee W, Liu X, Bandy D, Alexander GE, Thompson PM, Foster NL, Harvey DJ, de Leon MJ, Koeppe RA, Jagust WJ, Weiner MW, Reiman EM (2010) Twelve-month metabolic declines in probable Alzheimers disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimers Disease Neuroimaging Initiative. Neuroimage 51, 654-664.
84. Nordberg A, Amberla K, Shigeta M, Lundqvist H, Viitanen M, Hellstrom-Lindahl E, Johansson M, Andersson J, Hartvig P, Lilja A, Langstrom B, Winblad B (1998) Long-term tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 12, 228-237.
85. Keller C, Kadir A, Forsberg A, Porras O, Nordberg A (2011) Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimers disease patients. J Alzheimers Dis 24, 109-123.
86. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab:Aphase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363-372.
87. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69, 198-207.
88. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69, 1002-1010.
89. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
90. Selkoe DJ (2012) Preventing Alzheimers disease. Science 337, 1488-1492.
91. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimers disease: Recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 280-292.
92. Bouaziz M, Jeanmougin M, Guedj M (2012) Multiple testing in large-scale genetic studies. Methods Mol Biol 888, 213-233.